ViroGates A/S (OCSE:VIRO) Debt-to-Asset : 0.26 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is ViroGates A/S Debt-to-Asset?

ViroGates A/S's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. ViroGates A/S's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr5.30 Mil. ViroGates A/S's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was kr20.18 Mil. ViroGates A/S's debt to asset for the quarter that ended in Mar. 2024 was 0.26.

ViroGates A/S Debt-to-Asset Historical Data

The historical data trend for ViroGates A/S's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViroGates A/S Debt-to-Asset Chart

ViroGates A/S Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.22

ViroGates A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															-	0.33	0.36	0.22	0.26

Competitive Comparison of ViroGates A/S's Debt-to-Asset

For the Medical Devices subindustry, ViroGates A/S's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ViroGates A/S's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ViroGates A/S's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where ViroGates A/S's Debt-to-Asset falls into.

ViroGates A/S Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

ViroGates A/S's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	5.3)	/	24.555
	=	0.22

ViroGates A/S's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	5.3)	/	20.177
	=	0.26

ViroGates A/S (OCSE:VIRO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

ViroGates A/S Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of ViroGates A/S's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

ViroGates A/S (OCSE:VIRO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ViroGates A/S (OCSE:VIRO) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Banevaenget 13, Birkerod, DNK, DK-3460

Website

https://www.virogates.com

ViroGates A/S is a life science company that develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular, to make a clinical decision on hospitalization or discharge of emergency patients. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, and cancer. It has developed a product line called suPARnostic to make the suPAR test available as a commercially available test and the ambition is to get the test implemented and used for clinical decision-making.

ViroGates A/S (OCSE:VIRO) Headlines

No Headlines